At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
In Brief
A Phase 3 clinical trial evaluating Continue PD-1/PD-L1 Inhibitors treatment and Discontinue PD-1/PD-L1-1 inhibitor for Advanced Solid Tumors and 12 related conditions. Completed, enrolled 161 participants across 1 site.
Detailed Summary
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Study Details
Timeline
Interventions
Continued treatment with PD-1/PD-L1-1 inhibitor
Discontinued treatment with PD-1/PD-L1-1 inhibitor